The Effector That Impact The Maturation Of PBMNC-derived DCs

DCs are the most effective professional antigen-presenting cells for priming naive T cells, and in particular they have the potential to break tumor tolerance and induce tumor-specific immune response leading to tumor rejection. With the increasing knowledge of biological characteristics of DCs, recent studies have showed that DCs are of great value in tumor immune, transplant immune, and anti-infection immune. The data from phase I / II clinical trials showed that DCs vaccine had achieved encouraging effects in B lymphoma, melanoma, prostate cancer. But when DCs vaccine was used to treat solid tumor, most of these were considered as 'weak immunogeneic' tumor, the minimal effects didn't match the expected. Studies showed that the cancer could impair the process of the priming of naive T cells by DCs. So how to induce matured DCs, which can resist the inhibitory effector of TGF-β1, is necessary in preparation of DCs vaccine. 1. The effect of TGF-β1 to PBMNC-derived dendritic cellsTGF-β1 is one of major immune inhibitory factors present in tumor microenviroment, which has been demonstrated to impair DCs functions, including presentation of antigen, stimulatation of tumor-sensitized T lymphocytes, and migratation to draining lymph nodes. So effective DCs vaccine which can counteract the inhibitory of TGF-β1 will facilitate curative effect. Here we evaluate the change of DCs ability after induce...